Highlights d TSC2 deletion causes gene-dosage-dependent mTORC1 hyperactivity in neurodevelopment d TSC2 deletion causes alterations in pathways and genes associated with autism d TSC2 +/À and TSC2 À/À human neurons show stage-specific cellular and synaptic defects d mTORC1 inhibition corrects synaptic defects independently of early neurodevelopment
In Brief
The neurodevelopmental disorder tuberous sclerosis is caused by loss of TSC1/2, negative regulators of mTORC1. Combining genome editing technology and human stem cell differentiation, Costa et al. characterize stage-specific molecular, cellular, and synaptic alterations in neurons with TSC2 deletion and show that mTORC1 inhibition corrects defects in synaptic function independently of early neurodevelopmental abnormalities.
SUMMARY
Hyperfunction of the mTORC1 pathway has been associated with idiopathic and syndromic forms of autism spectrum disorder (ASD), including tuberous sclerosis, caused by loss of either TSC1 or TSC2. It remains largely unknown how developmental processes and biochemical signaling affected by mTORC1 dysregulation contribute to human neuronal dysfunction. Here, we have characterized multiple stages of neurogenesis and synapse formation in human neurons derived from TSC2-deleted pluripotent stem cells. Homozygous TSC2 deletion causes severe developmental abnormalities that recapitulate pathological hallmarks of cortical malformations in patients. Both TSC2 +/À and TSC2 À/À neurons display altered synaptic transmission paralleled by molecular changes in pathways associated with autism, suggesting the convergence of pathological mechanisms in ASD. Pharmacological inhibition of mTORC1 corrects developmental abnormalities and synaptic dysfunction during independent developmental stages. Our results uncouple stage-specific roles of mTORC1 in human neuronal development and contribute to a better understanding of the onset of neuronal pathophysiology in tuberous sclerosis.
INTRODUCTION
Increased activity of the mammalian target of rapamycin complex 1 (mTORC1) pathway has been implicated in autism spectrum disorder (ASD) and related neurodevelopmental disorders. Indeed, several monogenic disorders associated with a high rate of autism are caused by mutations in negative regulators of the pathway (Bourgeron, 2009) , and mTORC1 overactivation has been detected in temporal lobe of patients with idiopathic ASD (Tang et al., 2014) . Moreover, alterations in processes downstream of mTORC1 recapitulate ASD-like behavioral abnormalities and cellular pathology in mice (Santini et al., 2013; Gkogkas et al., 2013; Tang et al., 2014) . Thus, a better understanding of the molecular and cellular consequences of mTORC1 hyperfunction might help to identify novel targets for therapeutic intervention.
Tuberous sclerosis (TSC) is a severe multisystem disorder that presents with complex neuropsychiatric symptoms including autism, intellectual disability, and epilepsy (Crino et al., 2006; Rosser et al., 2006) . Neuroanatomical abnormalities include formation of cortical tubers, which are disorganized regions of the cortex characterized by the presence of dysplastic neurons with immature electrophysiological properties (Cepeda et al., 2012) . The disease is caused by heterozygous loss-of-function mutations in the genes coding for TSC1 or TSC2. Loss of heterozygosity due to somatic mutations of the functional allele has been detected in hamartomas, while its role in tuber formation remains controversial (Henske et al., 1997; Chan et al., 2004; Crino et al., 2010; Qin et al., 2010) . TSC1 and TSC2 form a heterodimeric complex that functions as a negative regulator of mTORC1 through the inhibition of Rheb, a Ras family GTPase (Inoki et al., 2003; Tee et al., 2003) . Increased mTORC1 kinase activity likely underlies TSC pathophysiology and is a pathological hallmark of brain malformations in patients (Talos et al., 2008) .
Deletion of TSC1/2 in animal models affects a wide range of neuronal processes, and inhibition of mTORC1 corrects specific cellular, neuroanatomical, and neurological phenotypes (Meikle et al., 2007 (Meikle et al., , 2008 Magri et al., 2011; Bateup et al., 2013; Tavazoie et al., 2005) . The direct cellular and synaptic consequences of TSC2 deletion in human neurons are unknown. Specifically, it is still unclear how increased TSC-mTORC1 pathway activity precipitates the onset of human neuronal dysfunction, how it alters multiple neurodevelopmental stages, and if and when phenotypes can be reversed.
Here, we used genome-engineered TSC2 +/À and TSC2 À/À human pluripotent stem cells to recapitulate the heterozygous loss of function underlying the disorder and study the effect of complete loss of TSC2 in neuronal development, respectively. Combining a neuronal differentiation protocol and molecular, cellular, and electrophysiological analyses, our results reveal the effects of alterations of the TSC2-mTORC1 pathway on human neurodevelopment and synaptic physiology.
RESULTS

Generation of an Allelic Series of TSC2 Deleted Human Embryonic Stem Cell Lines
Zinc-finger nuclease-mediated targeted gene disruption was used to generate heterozygous and homozygous deletions of TSC2 in the well-characterized SA001 human embryonic stem cell (hESC) line (Englund et al., 2010) , which we have previously used to study neuronal maturation (Dunkley et al., 2015) . We generated an isogenic allelic series of TSC2 deletions by inserting a neomycin selection cassette into one (TSC2 +/À ) or both (TSC2 À/À ) alleles or into the AAVS1 safe harbor locus (TSC2 +/+ ) ( Figure 1A ). Correct gene targeting was established by genomic PCR amplification across the disruption cassette (Figures S1A and S1B), and absence of additional genomic integrations was confirmed by targeted locus amplification (de Vree et al., 2014) ( Figure S1C ). Gene targeting resulted in decreased TSC2 protein levels in heterozygous lines and absence of the protein in homozygous clones ( Figure 1B ). To determine whether TSC2 mutation affected mTORC1 function in hESCs, we monitored phosphorylation levels of the downstream substrate 40S ribosomal protein S6 (RPS6) and found increased phosphorylation in TSC2 À/À , but not TSC2 +/À , lines ( Figure S1D ). We observed no differences in hESC colony morphology (Figures 1C and S1E), proliferation, pluripotency, or spontaneous differentiation capacity (data not shown). These results suggest that TSC2 deletion and mTORC1 hyperfunction do not grossly affect pluripotency of hESCs.
Deletion of TSC2 Causes Abnormal Structural Organization of Neuroectodermal Rosettes
In vivo, Tsc2 ablation leads to embryonic lethality and defective neural tube closure in mouse embryos at E11.5 (Kobayashi et al., 1999) . We therefore asked whether deletion of TSC2 alters hu-man neuroectodermal rosette formation, the in vitro correlate of in vivo cortical neuroepithelium development (Shi et al., 2012) . We induced neuroectodermal differentiation using a modified dual-SMAD inhibition protocol ( Figure S2A ; Experimental Procedures). Neuroepithelial progenitors expressed the forebrain rosette neural progenitor markers PLZF, Nestin, Pax6, and SOX1, suggesting efficient differentiation in control and mutant lines ( Figures 1E and S2C ; data not shown). The typical apicobasal polarity was mostly maintained in rosettes from all genotypes, as the tight junction protein zonula occludens 1 (ZO1) and M phase nuclei were oriented toward the lumen of the rosettes ( Figures 1E and S2C ) (Falk et al., 2012; Gö tz and Huttner, 2005) . However, TSC2 À/À rosettes were more heterogeneous in size due to formation of enlarged rosettes (Figures 1E, 1F, and S2D) . Cell size was comparable across genotypes at this stage, suggesting that enlarged rosette size was likely due to increased cell number ( Figure S2E ). Importantly, this cellular phenotype correlated with overactivation of the mTORC1 pathway in TSC2 À/À lines ( Figure 1D ). We conclude that biallelic TSC2 deletion causes mTORC1 hyperfunction in neuroectodermal rosettes, which in turn impairs their structural organization.
Deletion of TSC2 Alters Neuronal Proliferation, Differentiation, and Morphology in a Gene-Dosage-Dependent Manner During early neuroectodermal specification, no alterations were observed in TSC2 +/À lines. To investigate whether heterozygous TSC2 loss of function, mimicking the TSC patient genotype, leads to neural dysfunction during later stages of development, we generated neural stem cells (NSCs) that can be differentiated into functional neurons (Figures S2A and S2F-S2J; see Experimental Procedures for details). To model a physiologically relevant neuronal network with excitatory and inhibitory neuronal connectivity, we utilized a protocol that differentiates NSCs to glutamatergic and GABAergic neurons (HuC/D+ cells, 50.9% ± 3.2%; GABA+/HuC/D+ cells, 11.3% ± 5.8% at day 28 of differentiation; Figures 2A, S2A, and S2B) (Dunkley et al., 2015) .
TSC2 mutant lines showed early neuronal alterations. At day 14 of differentiation, TSC2 À/À showed a $55% reduction in the number of postmitotic (HuC/D+) neurons. The phenotype was less pronounced ($26% reduction) and transient in TSC2 +/À lines (Figures 2B, 2C, and S3G) . TSC2 À/À cells exhibited reduced expression of neuronal progenitor markers and aberrant proliferation already 7 days of differentiation ( Figures S3A-S3C ). We investigated the potential mechanisms underlying the decreased neuronal content in TSC2 À/À lines and found a small but significant increase in cell death of TSC2 À/À neurons at day 7 of differentiation ( Figure S3E ). In addition, TSC2 À/À lines showed an increased differentiation toward the astroglial lineage, as shown by upregulation of the astroglia marker NFIA and increase in GFAP+ cells at late stages of differentiation ( Figures S3D, S2L , and S2M). To understand the molecular correlates of the observed alterations in neuronal differentiation, we studied the expression of several genes and proteins relevant to neuronal development (Tables S1 and S2 ). TSC2 +/À and TSC2 À/À immature neurons showed increased expression of neural stem cell and proliferation markers (SOX2, NESTIN, and PCNA) and a concomitant downregulation of genes associated with neuronal maturation and synapse formation. Intriguingly, we observed dysregulation of the chloride transporters NKCC1 (SLC12A2) and KCC2 (SLC12A5), which affect neuronal excitability in response to GABA, are dynamically regulated during brain development and are altered in cortical tubers from TSC patients ( Figures 2E and S3F ) (Ben-Ari et al., 2012; Jagasia et al., 2009; Talos et al., 2012) . At day 14 of differentiation, TSC2 À/À (but not TSC2 +/À ) neurons showed increased soma size, recapitulating what is observed in cortical tubers and attributed to mTORC1 hyperfunction ( Figure 2B , right; and Figure 2D ) (Ruppe et al., 2014) . To assess morphological alterations in mature neurons ( Figures S2K and S2N ), we analyzed biocytin-filled 6-to 8-week-old neurons ( Figure 2F ). TSC2 À/À neurons exhibited increased dendritic arborization measured by Sholl analysis, increased soma size, and an $2-fold increase in total dendritic length ( Figures 2G, S3H , and S3I). TSC2 +/À neurons did not show gross morphological changes. In a correlation analysis, we observed a positive correlation of moderated t statistics values for transcripts and proteins between TSC2 +/À and TSC2 À/À lines compared to controls at days 14 and 41 of differentiation (r = 0.617 and r = 0.298 for transcripts and r = 0.552 and r = 0.444 for proteins at days 14 and 41, respectively; Figure 2H ). Cluster analysis revealed a trend toward downregulation of genes relevant for synaptic transmission in both TSC2 +/À and TSC2 À/À neurons. The cluster of proteins/transcripts with the largest effect included genes and pathways associated with autism including CNTNAP2, NLG3, and KCC2 ( Figure 2I ). In addition, we observed in both genotypes downregulation of RBFOX1, a splicing factor reduced in brains from idiopathic ASD patients ( Figure S3J ) (Fogel et al., 2012 , Voineagu et al., 2011 . In the aggregate, these data indicate that monoallelic deletion of TSC2 causes persistent dysregulation of ASD-relevant genes that is similar to that observed in TSC2 À/À cells but whose extent remains below the threshold required to elicit (legend continued on next page) most of the early cellular phenotypes seen in the full knockout. In addition, our molecular analysis suggests that TSC2 deletion leads to alterations in synapse biology in both genotypes.
TSC2 Heterozygous Deletion Leads to mTORC1 Hyperfunction in Differentiating Neuronal Cultures
To address whether the observed molecular and cellular deficits correlated with alterations in mTOR signaling, we monitored the phosphorylation status of mTORC1 downstream substrates in response to physiologically relevant modulators (insulin-like growth factor [IGF] and brain-derived neurotrophic factor [BDNF]) and known inhibitors (rapamycin and nutrient starvation) of the pathway. As expected, TSC2 protein was reduced to $50% in TSC2 +/À lines and absent in TSC2 À/À lines (Figures S4A and S4B) . Lines from all genotypes exhibited an IGF1dependent increase in phosphorylation of the mTORC2 substrate AKT at serine 473 (Sarbassov et al., 2005) in both NSCs (Figures 3A and S4E) and neurons ( Figures 3B and S4F ). In contrast, BDNF elicited a response only in neurons, consistent with functional maturation of the culture ( Figures 3A, 3B , S4C, and S4D). Phosphorylation of mTORC1 targets S6 and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) showed TSC2 gene-dosage-dependent alterations. TSC2 À/À cells showed constitutive activation of mTORC1 as shown by increased phosphorylation of S6 and 4EBP1 even upon withdrawal of growth factors, a condition which silences the pathway in control lines. Furthermore, TSC2 À/À lines exhibited a marked reduction of AKT phosphorylation, previously ascribed to mTORC1-dependent negative feedback signaling (Shah and Hunter, 2006, Harrington et al., 2004) . Indeed, the reduction was partially reverted upon rapamycin treatment (from $34% to $84% of TSC2 +/+ at day 0 and from $12% to $42% of TSC2 +/+ at day 35, in the presence of growth factors without and with rapamycin, respectively; Figures 3A, 3B, and S4H) . Surprisingly, although we could not observe gross differential regulation between control and TSC2 +/À lines at the NSC stage ( Figure 3A ), phosphorylation of S6 and 4EBP1 was increased in TSC2 +/À lines at day 35 (Figures 3B and S4D; quantification in Figure S4H ).
Interestingly, upon differentiation, negative regulators of the mTOR pathway were upregulated in control lines (TSC1 and TSC2, $3-fold; PTEN, $10-fold), suggesting a tight regulation of the pathway in neurons (Figures S4A and S4B) . In mature neurons, TSC1 protein expression was reduced in TSC2 +/À and TSC2 À/À lines ( Figures S4A and S4B ). This suggests that the mTORC1 pathway is tightly regulated during neuronal maturation and that an $50% reduction in TSC2 leads to a molecular phenotype in neurons. Moreover, homozygous deletion of TSC2 leads to constitutive activation of mTORC1 and dysregulation of feedback signaling pathways as observed in cortical tubers (Ruppe et al., 2014) .
mTORC1 Inhibition Corrects Excitability and Synaptogenesis Deficits Independently of Early Neurodevelopmental Alterations
We next asked if, and at what stage during neuronal differentiation, cellular and electrophysiological phenotypes could be corrected by inhibition of mTORC1. Rapamycin treatment of (H) Correlation analysis between TSC2 +/À and TSC2 À/À lines of t statistics values compared to TSC2 +/+ lines calculated for 254 transcripts and 196 proteins at day 14 and day 41 of differentiation. Pearson correlation values are indicated. Red line is calculated using LOWESS smooth splines. (I) Cluster analysis (using Euclidean distance and Ward clustering) based on the t statistics representing significance of change relative to wild-type (WT) for both genotypes at day 41. Analysis on genes for which both protein (P) and transcript (T) measurements were available. A sub-cluster around EPHB1 showed very marked and consistent effects. See also Figures S2 and S3 and Tables S1 and S2. Cell Reports 15, 1-10, April 5, 2016 5 TSC2 À/À NSCs during the first 7 days of differentiation reverted cell density and soma size to control levels but failed to correct the deficit in neuronal differentiation ( Figures 4A and 4B ). The latter phenotype was partially ameliorated when the treatment was applied on proliferating NSCs during the patterning stage, suggesting that earlier application of rapamycin during neuroectodermal differentiation might be beneficial ( Figure S4I ).
In mature neurons, whole-cell patch-clamp recordings revealed that TSC2 À/À neurons had an $50% reduction in electrical input resistance and an $2-fold increase in membrane capacitance ( Figures 4C and S4J ), which correlated with increased total dendritic length of individual cells ( Figure S4K ). Normalizing the input conductance by the capacitance in individual cells revealed no significant differences between genotypes, indicating that the conductance density of open ion channels at the resting membrane potential was not significantly different (data not shown) and suggesting that the alterations in passive membrane properties are likely due to increased cell size. Since the increased capacitance and decreased input resistance might impact electrical excitability, we measured action potential (AP) firing in response to 1-s current pulses with increasing current amplitudes. While TSC2 +/À neurons responded similarly to control cells, TSC2 À/À neurons required a 2-fold-larger current amplitude to generate the same frequency of AP firing (Figures 4D and 4E) . Similar results were obtained when measuring the AP firing probability in response to brief 10-ms current pulses with increasing amplitude (Figures S4L and S4M ). The functional properties of voltage-gated sodium and potassium channels were unlikely to be different, since the shapes of individual APs were indistinguishable across genotypes ( Figures S4N-S4P ). To test whether changes in electrical excitability were due to enhanced mTORC1 activity, we treated cells for 7 weeks with 2 nM rapamycin, a concentration that inhibits mTORC1 signaling ( Figure S4G ), starting at day 7, after early neuronal differentiation had occurred. Remarkably, after treatment, both passive membrane properties and AP firing were indistinguishable from control ( Figures 4C-4E , S4J, and S4L).
Our molecular analysis suggested alterations in excitatory synaptic function in TSC2 +/À and TSC2 À/À neurons ( Figure 2I ). To analyze glutamatergic synapse formation and excitatory synaptic transmission, we recorded spontaneous excitatory synaptic currents (sEPSCs) and miniature excitatory synaptic currents (mEPSCs) in the presence of the GABA A -receptor antagonist gabazine (4 mM). The frequency of sEPSCs (0.57 ± 0.15Hz, n = 12, control) was significantly reduced in TSC2 +/À as well as in TSC2 À/À neurons relative to control lines in a gene-dosagedependent manner (0.28 ± 0.05 Hz, p < 0.05, n = 24 and 0.16 ± 0.04 Hz, p < 0.01, n = 11, respectively; Figures 4F and 4G). The phenotype was reverted by long-term (7 weeks starting at day 7 of differentiation), but not acute (2 hr starting at 8 weeks of differentiation), treatment with rapamycin. To understand whether the phenotype could be rescued at late developmental stage by longer treatment, we applied rapamycin for 3-4 weeks starting at 6 weeks of differentiation. The treatment fully corrected the deficit in sEPSCs frequency (TSC2 +/À with 3-to 4-week rapamycin: 0.69 ± 0.22 Hz, n = 7). To test whether the reduction in frequency of sEPSCs was caused by decreased excitability or a reduced number of synaptic connections, we recorded mEPCs in the presence of 0.5 mM TTX. Similarly to spontaneous synaptic currents, mEPSC frequency (0.15 ± 0.04 Hz, n = 24) was reduced in mutant neurons (TSC2 +/À : 0.04 ± 0.02 Hz, n = 7; TSC2 À/À : 0.01 ± 0.01, n = 11), indicating a reduced number of glutamatergic synapses, and the phenotype was corrected by chronic rapamycin treatment ( Figures  4H and 4I ). Furthermore, rapamycin could correct the slight but significant increase in the amplitude and decay time course of average mEPSCs in TSC2 À/À neurons ( Figures 4J-4L ).
Taken together, these data show that neuronal and synaptic alterations, including a deficit in glutamatergic synaptic transmission, are triggered in a TSC2-gene-dosage-dependent manner and can be corrected by pharmacological mTORC1 inhibition. Importantly, synaptic defects are corrected even when rapamycin treatment is started after the establishment of synaptic network connectivity. Untreated: ten wells/plate, 27 fields/well, four plates; treated: three wells, 27 fields/well. ***p < 0.001, ****p < 0.0001. (C) Input resistance of day 56-63 differentiated neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2 +/+ : n = 37, TSC2 +/À : untreated n = 39, treated n = 4; TSC2 À/À : untreated n = 31, treated n = 27. (D) Representative recordings of action potentials (AP) induced by somatic current injections of 18 and 28 pA. (E) AP firing frequency-current relationship calculated from recordings of action potentials induced by a 1-s pulse of somatic current injections DI = 2 pA. Curve was constructed using Boltzmann sigmoidal fit in GraphPad Prism. (F) Frequency of spontaneous EPSCs (5-min recording in the presence of 4 mM gabazine). TSC2 +/+ : n = 12; TSC2 +/À : untreated n = 24, treated for 2 hr with 20 nM rapamycin n = 12, treated with 2 nM rapamycin for 3-4 weeks n = 7 or for 7 weeks n = 12; TSC2 À/À : untreated n = 11, treated with 2 nM rapamycin for 7 weeks n = 10. (G) Representative traces of sEPSCs quantified in (F). (H) Frequency of mEPSC in day 56 -63 differentiated neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2 +/+ : n = 24; TSC2 +/À : untreated n = 7, treated n = 5; TSC2 À/À : untreated n = 11, treated n = 12. (I) Representative traces of mEPSCs quantified in (H) recorded in the presence of 0.5 mM TTX and 4 mM gabazine. (J) Representative traces of mEPSCs. Black line represents the average of 25 single events. Gray line represents the biexponential fit of the average trace. (K) Amplitudes of mEPSCs in neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2 +/+ : n = 18; TSC2 +/À : untreated n = 5, treated n = 4; TSC2 À/À : untreated n = 5, treated n = 6. (L) Decay time constants of mEPSCs in neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2 +/+ : n = 18; TSC2 +/À : untreated n = 5, treated n = 4; TSC2 À/À : untreated n = 5, treated n = 6. Bar graphs represent mean ± SEM (C, E, F, H, K, and L); *p < 0.05; **p < 0.01. See also Figure S4 .
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DISCUSSION
The pathophysiological mechanisms underlying neuroanatomical and neurological alterations in patients affected by TSC are largely unknown. Here, we show that TSC2 deletion leads to exaggerated mTORC1 signaling during differentiation of human neurons in a gene-dosage-dependent manner, and this correlates with molecular and cellular alterations at multiple developmental stages. We show that TSC2 deletion alters the structure of human neuroectodermal rosettes, providing an in vitro correlate of neural tube formation deficits observed during in vivo embryonic development. Interestingly, abnormal rosette organization has been recently reported in hiPSCs carrying 15q11.2 microdeletion, a risk factor for schizophrenia and autism, supporting a role for early neurodevelopmental defects in neuropsychiatric disorders (Yoon et al., 2014) . At later stages, we show that heterozygous loss of TSC2 results in a transient delay in early neuronal differentiation. Deficits in neuronal differentiation have been suggested to lead to abnormal brain wiring and could contribute to the altered connectivity observed in TSC patients (Krishnan et al., 2010; La Fata et al., 2014; Baumer et al., 2015) . Furthermore, we demonstrate that heterozygous and homozygous loss of TSC2 leads to altered synaptogenesis and transmission. By inhibiting mTORC1 at different developmental stages, we show that early neurodevelopment and synaptogenesis can be uncoupled and corrected independently of each other. Indeed, excitatory synapse reduction can be corrected in both genotypes by long-term mTORC1 inhibition even after the onset of early differentiation deficits. Importantly, the correction is achieved even when the treatment is started at late differentiation stages, after synaptic network connectivity has been established.
Cortical tubers are a common neuropathological feature in TSC patients and their role in epilepsy and cognitive impairment is under close scrutiny (Jansen et al., 2007 (Jansen et al., , 2008 Doherty et al., 2005; Major et al., 2009) . We show that homozygous deletion of TSC2 recapitulates molecular, cellular, and electrophysiological features observed in dysplastic neurons from cortical tubers. Notably, alterations are dependent on mTORC1-hyperactivity, as they can be corrected by rapamycin treatment. Extending the functional characterization of our TSC2 mutant neurons will contribute to understand the role of altered mTORC1 signaling, excitability, and synaptic connectivity in the onset of neuronal network dysfunction and of epilepsy, a pathological feature associated with TSC and involved in the development of ASD.
Patients affected by TSC present with autism (50%) and comorbid symptoms including epilepsy (80%-90%) and varying degrees of intellectual disability (45%) (Jeste et al., 2008; Crino et al., 2006; Curatolo and Bombardieri, 2008) . ASD is characterized by a remarkable heterogeneity in genetic causes and clinical manifestations. Consequently, identifying convergence in ASD biology remains an elusive challenge. Using TSC as a model of monogenic forms of ASD, we have characterized phenotypes in human neurons including deficits in synaptogenesis and alterations in pathways and genes previously associated with ASD. Extending this analysis to multiple genetically defined models of ASD will provide an unprecedented opportunity to link human genetics to neuronal phenotypes and potentially identify shared pathophysiological mechanisms.
EXPERIMENTAL PROCEDURES
Genome Editing
Plasmids encoding zinc-finger nucleases (ZFNs) targeting exon 11 of TSC2 (CompoZr knockout ZFN) and mRNA encoding ZFNs targeting exon 1 of the PPP1R12C locus (CompoZr Targeted Integration Kit) were from Sigma. Targeting constructs harboring a loxP-flanked PGK promoter-driven neomycin phosphotransferase cassette surrounded by sequences homologous to the genomic locus adjacent to the ZFN cut sites were synthesized de novo. Constructs were electroporated into SA001 hESCs, which were selected with 0.2 mg/ml G418 (Life Technologies), and clones with site-specific cassette insertions were identified by PCRs from genomic DNA. For more detail, refer to Supplemental Experimental Procedures.
Neuronal Differentiation
For patterning, NSCs were plated on polyornithin-/laminin-coated dishes at 10,000-15,000 cells/cm 2 in basal medium with 100 ng/ml FGF-8 (Peprotech), 200 ng/ml sonic hedgehog (Peprotech), and 100 mM ascorbic acid 2-phosphate (Sigma) and cultured for 1 week. For differentiation, the resultant progenitors were plated at 35,000-50,000 cells/cm 2 in basal medium with 20 ng/ml BDNF, 10 ng/ml glial cell-derived neurotrophic factor (GDNF; Peprotech), 500 mM dibutyryl cyclic AMP (Sigma), and 100 mM ascorbic acid 2-phosphate. For more detail, refer to Supplemental Experimental Procedures.
Electrophysiology
Recordings were performed at 22 C-24 C. Cells were superfused with ACSF containing (in mM): 123 NaCl, 25 D-Glucose, 10 HEPES, 25 NaHCO 3 , 5 KCl, 1 NaH 2 PO 4 , 2 CaCl 2 and 1 MgCl 2 . Internal solution contained (in mM): 140 KCl, 10 EGTA, 10 HEPES, 2 MgCl 2 , 2 Na 2 ATP, 1 Phosphocreatine and 0.3 NaGTP with a pH of 7.28. Gluconate-based solution contained 135 mM K-gluconate, 20 mM KCl, 10 mM HEPES, 0.1 mM EGTA, 2 mM MgCl 2 , 2 mM Na 2 ATP, 1 mM phosphocreatine, and 0.3 mM NaGTP. Borosilicate glass patch pipettes (2.5-4.0 MU) were used. Cells were patched in the whole-cell configuration with a stable series resistance of R S < 20 MU. sEPSCs and mEPSCs were recorded at a membrane potential of À70 mV in voltage-clamp mode. APs were elicited in current-clamp mode via current injections of either 1 s or 20 pulses of 10 ms duration. For more detail, refer to Supplemental Experimental Procedures.
Imaging
Fluorescent images were acquired using a Leica TCS SP5 (Leica Microsystems) inverted microscope, Opera High Content Screening System (Perkin Elmer) or Operetta High Content Imaging System (PerkinElmer). For data analysis, refer to Supplemental Experimental Procedures.
Western Blot
Protein samples were resolved on NuPAGE 4%-12% gels and transferred to nitrocellulose membranes using the iBlot Dry Blotting System (Life Technologies). Blot scans were acquired using a Li-COR scanner (Odyssey) and analyzed using the Image Studio Software (Li-COR Biosciences). Antibodies are listed in Supplemental Experimental Procedures.
Transcriptome Analysis
Real-time qPCR was performed with TaqMan Gene Expression assays (Life Technologies) using a 96.96 Dynamic Array (Fluidigm). For data analysis, refer to Supplemental Experimental Procedures.
Mass Spectrometry
Experiments and peak selection were performed as described previously (Dunkley et al., 2015) . For data analysis, refer to Supplemental Experimental Procedures. 
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Supplemental Tables
Supplemental Experimental Procedures
Genome editing hESC culture. The hESC line SA001 (NIH Registration Number 0085; Cellectis, Sweden) was cultured on hESC-qualified Matrigel (BD Biosciences) in mTESR1 (STEMCELL Technologies) with daily medium replacement. Upon reaching confluence, colonies were dissociated to single cells using Accutase (LifeTechnologies) and subcultured at a ratio of 1:10 -1:20 in the presence of 10 µM Y-27632. Constructs. Plasmids encoding a pair of zinc finger nucleases (ZFNs) targeting exon 11 of TSC2 (CompoZr Knockout ZFN) were from Sigma. The ZFN recognition site is CATGACCTGTTGACCacggtGGAGGAGCTGTGTGA, where upper and lower case letters denote the ZFN binding and cut sites, respectively. mRNA encoding ZFNs targeting exon 1 of the PPP1R12C (also known as AAVS1) locus was from Sigma (CompoZr Targeted Integration Kit). Targeting constructs harboring a loxPflanked phosphoglycerate kinase promoter (PGK)-driven neomycin phosphotransferase cassette (loxP-PGKneo-loxP; Suppl. Fig. 1 ) surrounded on either side by 400 bp of sequence homologous to the genomic locus immediately adjacent to the ZFN cut sites, were synthesized de novo, subcloned into the EcoRV site of pUC57 and sequence-verified (GenScript). Genome targeting. One µg each of the ZFN plasmids (for TSC2) or one vial of ZFN mRNA (for AAVS1) and 1 µg of targeting vector were introduced into 2×10 6 SA001 hESCs by electroporation (4D Nucleofector with X Unit, P3 Solution, program DN-100; all from Lonza, Switzerland), and cells plated in the presence of 10 µM Y-27632. Selection with 0.2 g/ml G418 (LifeTechnologies) was started two days later. After ten days of selection, resistant colonies were manually isolated, transferred to multiwell plates and separately cultured without selection. Clones with site-specific cassette insertions were identified by PCRs from genomic DNA with the following oligonucleotide primer pairs: TSC2 locus, TSC2_F1 + Neo_R and Neo_F + TSC2_R1; AAVS1 locus, AAVS1_F + Neo_R and Neo_F + AAVS1_R. Correctly targeted clones were further subcloned done by limited dilution, expanded, and re-analyzed by genomic PCR.
Genomic characterization
Site-specific integration. Correct genomic insertion of the selection cassettes was confirmed by PCR amplification from genomic DNA, using the primer pairs described above, followed by direct sequencing of the PCR products. For TSC2-targeted cell lines, we additionally amplified the targeted genomic region with oligonucleotides TSC2_F2 and TSC2_R2, which prime distal to the targeting vector's homology region and distinguish heterozygous (TSC2+/-) from nullizygous (TSC2-/-) lines. Random integrations. Absence of additional, non-specific cassette insertions was confirmed by targeted locus amplification (TLA) followed by deep sequencing (Cergentis, Netherlands).
Cell culture and neuronal differentiation
Neuronal cell culture media. N2B27 medium is a 1:1 mixture of DMEM/F12 (1:1) medium with GlutaMAX I and Neurobasal medium, containing 1×N2 supplement, 1×B27 supplement minus Vitamin A, and 50 µM βmercaptoethanol (all from LifeTechnologies). NEP medium is N2B27 medium containing 5 ng/ml FGF-2, 250 ng/ml noggin (R&D Systems or Peprotech), and 20 µM SB 431542 (Tocris). FEB medium is N2B27 medium containing 10 ng/ml FGF-2 (Peprotech), 10 ng/ml EGF (R&D Technologies), and 20 ng/ml BDNF (Peprotech). SFA medium is N2B27 medium containing 100 ng/ml FGF-8 (Peprotech), 200 ng/ml sonic hedgehog (Peprotech) and 100 µM ascorbic acid 2-phosphate (Sigma). BGAA medium is N2B27 medium containing 20 ng/ml BDNF, 10 ng/ml GDNF (Peprotech), 500 µM dibutyryl cyclic AMP (Sigma) and 100 µM ascorbic acid 2phosphate. Generation of neural precursor cells (NPCs) . NPCs were generated from hESCs using a modified dual SMAD inhibition protocol (Chambers et al. 2009 ). hESCs were dissociated to single cells and plated into AggreWell-800 plates (STEMCELL Technologies) at a density of 5,000 cells per microwell in NEP medium supplemented with 10 µM Y-27632. After five days, aggregates were recovered, plated on polyornithine-/laminin-coated (PL) dishes in NEP medium and cultured for an additional three days to form neural rosettes. Rosettes were isolated manually and replated on PL dishes in NEP medium. Upon reaching confluence, cells were dissociated with 0.05% trypsin/EDTA solution (LifeTechnologies) and plated at 100,000 cells/cm 2 on PL dishes in FEB medium. Cells were cultured under these conditions with passaging every 2 -3 days for ca. 15 population doublings (PDs), followed by a stepwise decrease in plating density to 25,000 cells/cm 2 within ca. 10 PDs. Medium was replaced daily throughout the entire NPC derivation procedure. NPC lines were characterized by FACS and immunocytochemical analyses. Neuronal differentiation. NPCs were dissociated with trypsin/EDTA, plated on PL dishes at 10,000 -15,000 cells/cm 2 in SFA medium, and cultured for one week with medium replacement after four days. The resultant progenitors were dissociated with trypsin/EDTA, plated on PL dishes at 35,000 -50,000 cells/cm 2 in BGAA medium and differentiated for up to 10 weeks with biweekly medium replacement.
Transcriptome analysis
Fluidigm analysis. For characterization of TSC2 genome edited lines, RNA extraction was automated using QIAsymphony RNA extraction kit on QIAsymphony (QIAGEN), RNA (100 ng) was reverse transcribed using ABI High Capacity cDNA kit, cDNA was pre-amplified using Taqman PreAmp master mix (LifeTechnologies) in the presence of Taqman assays (all LifeTechnologies) in a 16 cycle run. Pre-amplified cDNA samples were analyzed by qPCR using a primed 96.96 Dynamic Array using the IFC Controller HX and run on a BioMark II station (all Fluidigm), according to the manufacturer's instructions. Data were normalized to the average of three housekeeping genes (RPLO, GAPDH and TBP) weighted to the quality of the measurement as assessed by the instrument. Relative expression levels were calculated using the 2 -∆∆Ct method. Statistical analysis was performed as described in Mass spectrometry section. qPCR analysis. RNA was extracted using RNeasy Micro kit (Qiagen), reverse transcribed using Superscript III First Strand (Invitrogen) and qPCR performed using RealTime Ready RNA virus master (Roche). Data were normalized to TBP levels and relative expression levels were calculated using the 2 -∆∆Ct method.
Mass spectrometry
Experiments and peak selection were performed as described in (Dunkley et al. 2015) . Data analysis was performed to obtain relative quantities applying the function "quantification by sample" from the R package published previously (Choi et al. 2014 ) enriched with an additional filtering algorithm which discharged all fragment ions with Spearman's rank correlation coefficient <0.8 in one of the possible pairs where more than two fragment ions from the same peptide of a protein were available. An empirical Bayes moderated t-test (Smyth 2004 ) was used to perform statistical analysis of changes in protein levels between conditions (day and clone). Duplication of data by experiment was taken into account via the approach described in (Smyth et al. 2005) .
Western blot
Cells were rinsed with N2B27 medium, collected in phosphate-buffered saline (PBS) and lysed in RIPA buffer. Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktails 1, 2, and 3 (all Sigma) were added to RIPA buffer before lysis. Protein concentration was quantified by BCA assay (Pierce) using BSA to generate standard curves. Protein samples were resolved on NuPAGE 4-12% gels and transferred to nitrocellulose membranes using the iBlot Dry Blotting System (all LifeTechnologies). Membranes were incubated in blocking buffer (Odyssey) (1:1 in PBS with 0.05% Tween 20). Membranes were incubated with primary and secondary antibodies overnight and for 1.5 h, respectively. Blot scans were acquired using a LI-COR scanner (Odyssey) and analysis and quantification were performed using the Image Studio Software (LI-COR Biosciences).
Immunocytochemistry
Cells cultured in 96-well (BD Falcon) were fixed in 4% paraformaldehyde (PFA) in PBS for 10 minutes, permeabilized with 0.25% (v/v) Triton in PBS for 5 minutes and incubated for 45 minutes in blocking solution (10% BSA in PBS w/v). Primary antibodies were diluted in 3% BSA in PBS (w/v) and incubated overnight at 4°C. Secondary antibodies were diluted in 3% BSA in PBS (w/v) and incubated for 1.5 h at room temperature. Cells were incubated with DAPI (1 µg/ml) in PBS for 5 minutes at room temperature. Wells were washed with PBS and stored at 4°C. To assess cell morphology of recorded neurons, the cells were filled with biocytin (Molecular Probes, 2 mg/ml) via the internal pipette solution (see below). After recordings, cells were fixed overnight in 4% PFA and stained using fluorescent FITC-Avidin-D in the presence of 0.25% (v/v) Triton.
Imaging
Confocal fluorescent images were acquired using a Leica TCS SP5 (Leica Microsystems) inverted microscope. Maximum projections of stacks acquired along the z-axis were obtained using LAS-AF software. Quantification of rosettes size was performed using ImageJ. For analysis of cell identity, fluorescent images were acquired using Opera High Content Screening System (Perkin Elmer) and images quantified using Acapella Imaging software (Perkin Elmer). For analysis of cell growth, neuronal differentiation and soma size images were acquired using Operetta High Content Imaging System (PerkinElmer) and images were analyzed with the Harmony 3.1 High Content Imaging and Analysis Software (PerkinElmer).
Early differentiation phenotypic assay
For treatment of differentiating cells: rapamycin was added at the beginning of differentiation in BGAA medium 4 hours after seeding and at day 4 of differentiation. For treatment of proliferating NSCs: rapamycin was added at the beginning of patterning in SFA medium 4 hours after seeding and at day 4, and at the beginning of differentiation in BGAA medium 4 hours after seeding and at day 4. Cells were fixed and processed for immunostaining and analysis at day 7 of differentiation. Acquisition was performed using Operetta High Content Imaging System (PerkinElmer) and images were analyzed with the Harmony 3.1 High Content Imaging and Analysis Software (PerkinElmer).
FACS analysis
Neural stem cells were collected using 0.05% Trypsin/EDTA and incubated with antibodies anti-CD56-PE (1:20) (BD) and anti-CD271-PE (1:4000) (BD) for 20 minutes at 4°C. Expression of surface markers was analyzed by flow cytometry (FACSCanto). Neuroectodermal progenitor cells were collected selectively isolating rosettes at day 2.5 of differentiation which were then dissociated into single cells using Accutase (Stem Cell Technologies). For the characterization of cell size using the FSC-A parameter, dead cells and cell aggregates were excluded from the analysis based on 7-AAD staining and FSC-H/ FSC-A values correlation, respectively.
Electrophysiology
All recordings were performed at room temperature (22-24 °C) on hESCs derived neurons at day 42-80 (6-10 weeks) of differentiation. Briefly, neurons were grown on glass cover slips untreated or treated with rapamycin (2 nM for long term treatment, 20 nM for acute treatment). In treated cells, rapamycin (Tocris Bioscience) was added to the external solution during all recordings. Cells were visualized with a 40× NA0.8 water immersion objective (Carl Zeiss Microscopy GmbH, Jena, Germany) using infrared differential interference contrast (IR-DIC) video microscopy and recorded using a MultiClamp 700B amplifier (Molecular Devices, Palo Alto, CA, USA). Data were filtered at 5 kHz and digitized at 10 kHz using a CED Power1401 interface (Cambridge Electronic Design, Cambridge UK). Data acquisition and analysis were performed using custom software (FPulse, U. Fröbe, Physiological Institute Freiburg) running under IGOR Pro 6.12 (WaveMetrics, Lake Oswego, OR) and the open source software Stimfit (C. Schmidt-Hieber, University College London, https://code.google.com/p/stimfit/). Cells were continuously superfused with ACSF containing (in mM): 123 NaCl, 25 D-Glucose, 10 HEPES, 25 NaHCO 3 , 5 KCl, 1 NaH 2 PO 4 , 2 CaCl 2 and 1 MgCl 2 . Patch pipettes (2.5 -4.0 MΩ) were pulled from borosilicate glass tubing with 2 mm outer diameter and 0.5 mm wall thickness (Hilgenberg, Malsfeld, Germany) and filled with internal solution containing (in mM): 140 KCl, 10 EGTA, 10 HEPES, 2 MgCl 2 , 2 Na 2 ATP, 1 Phosphocreatine and 0.3 NaGTP with a pH of 7.28. For some experiments a gluconate-based solution was used containing (in mM): 135 K-gluconate, 20 KCl, 10 Hepes, 0.1 EGTA, 2 MgCl 2 , 2 Na 2 ATP, 1 Phosphocreatine and 0.3 NaGTP. Cells were patched in the whole-cell configuration with a stable series resistance of R S < 20 MΩ. Spontaneous synaptic activity and miniature excitatory postsynaptic currents (mEPSCs) were recorded at a membrane potential of -70 mV in voltage clamp mode. For detection and analysis of sEPSCs and mEPSCs a template matching algorithm implemented in Stimfit was used (Clements and Bekkers 1997) . Briefly, in a first step, large synaptic events were averaged and fitted with an exponential rise and decay. Second, this fitted function was used as an amplitude-scaled template, to match synaptic events by temporally sliding it over the recorded current trace and adjusting the amplitude by minimizing sum of standard error. Finally, the automatically detected events were visually controlled and false positive events were manually deleted. Results are presented as mean ± SEM. APs were elicited in current clamp mode via current injections of either 1 s or 20 pulses of 10 ms duration for long and short pulse protocols, respectively. Results were presented as a frequency-current (f-I) relationship curve for long pulses or as the percentage of action potentials elicited by the indicated current injection step for short pulses. Data were fitted using sigmoidal Boltzmann function in GraphPad Prism Version 5.0 (GraphPad Software, Inc., San Diego, CA, USA).
Oligonucleotide primers
Name
Sequence Purpose Neo_F1 5'-AATGGGCTGACCGCTTCCTC-3'
Genomic PCR screen of hESC clones generated by genome editing Neo_R1 5'-TGTTCAATGGCCGATCCCAT-3' AAVS1_F 5'-TTGCTCTCTGCTGTGTTGCT-3' AAVS1_R 5'-TGACCAACCATCCCTGTTTT-3' TSC2_F1 5'-GAGGCTGGACCTGGGAGAGG-3' TSC2_R1 5'-TCATCGGGCATCCTGAGACC-3' TSC2_F2 5'-ACAGCTTCAGTTTCCGCAGT-3' Distinguishing TSC2 +/and TSC2 -/clones TSC2_R2 5'-ATGCGTGAATATGCGTGTGT-3' Neo_F2 5'-ATGGGATCGGCCATTGAACA-3' Targeted locus amplification Neo_R2 5'-GAGGAAGCGGTCAGCCCATT-3' 
Primary and secondary antibodies
